Abdul Mannan: Why AML inv(16) Isn’t Just “Favourable”
Dr Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, posted on LinkedIn:
“The ‘Harlequin’ Leukemia: Why AML inv(16) Isn’t Just ‘Favourable’
AML with inv(16)(p13.1q22) is one of the most visually striking and biologically distinct subtypes we see. Textbooks call it ‘favourable.’ Clinicians know it’s more complicated.
1. Morphology: The Harlequin Clue
- The FAB M4Eo marrow gives it away.
- Those eosinophils with mixed orange and purple granules are almost diagnostic.
- And if the blasts show CD2 positivity, you already know what the karyotype is likely to say.
2. The Engine: CBFB::MYH11
- The fusion traps RUNX1 in the cytoplasm, freezing maturation and driving the disease. Classic CBF biology.
3. The ELN 2022 Twist: KIT Isn’t a Deal-Breaker
- About one-third carry KIT mutations, especially D816V.
- Yes, relapse risk climbs.
- But ELN 2022 keeps CBF-AML in the favourable group regardless because overall survival remains excellent.
Practical point:
- Not a transplant trigger in CR1, but absolutely a reason for closer molecular surveillance.
4. Treatment: Do It Properly or Don’t Call It Favourable
- Induction:
- CD33-high disease → add Gemtuzumab Ozogamicin where possible.
- Consolidation:
- No shortcuts.
- This subtype demands high-dose Cytarabine (HiDAC). Standard-dose consolidation is simply not enough.
5. MRD: Your Early Warning System
- Monitor the CBFB::MYH11 transcript every 3 months for two years.
- A rising log value means molecular relapse long before counts crash.
Bottom Line
- inv(16) isn’t “easy AML.”
- It’s highly curable only when treated with precision: recognise the morphology, respect the molecular modifiers, use GO in induction, and commit to HiDAC consolidation.
How are you using Gemtuzumab in your CBF-AML pathways? And what’s your approach to KIT-mutated cases in CR1? Happy to hear how others are tackling this.”
Follow the latest with Hemostasis Today.
-
Mar 2, 2026, 17:22Hematologists and Oncologists Recognize Their Role in Specialized VA Care Despite Ongoing Knowledge Gaps – JTH
-
Mar 2, 2026, 17:04Fernando Corrales-Medina: An Evidence-Based Platform Promoting Early Recognition and Evaluation of VWD
-
Mar 2, 2026, 16:56Mbunya S. Misiani: Changing the Narrative on Bleeding Disorders Across Africa
-
Mar 2, 2026, 16:51Ofoke Chiamaka: Rehabilitation Is Not Just Muscle Training, It Is Brain Retraining
-
Mar 2, 2026, 16:41Paul Bolaji: Beyond Acute Stroke Care – Independent Integrated Living After Stroke
-
Mar 2, 2026, 16:37Gianluca Franceschini: Precision Medicine Is Only Truly Effective If It Is Inclusive
-
Mar 2, 2026, 16:34Maha Othman: Calling a Guest Editor for Current Opinion in Hematology
-
Mar 2, 2026, 16:30Tareq Abadl: Erythropoiesis – The Cellular Engineering Behind Oxygen Delivery
-
Mar 2, 2026, 16:28Tagreed Alkaltham: Blood Management in Times of Crisis